AndroGel 1.62% May Lead to Heart Attack and Stroke

AndroGel 1.62% May Lead to Heart Attack and Stroke When witnessing a product being advertised on television, most understand that the company backing the product is dramatizing situation for their manufactured goods to sell. This understanding does not fall short of pharmaceutical manufacturers and in actuality, is probably the most embellished form of produced mass goods yet. Although advertised as being the solution to a health issue, most of the companies point out the benefits and rush through the risks, saturating the market with positive claims to support their merchandise. This issue has been highlighted by the rampant advertising of testosterone products when no one has proved its worth or the expected risks. By 2011, 1 in 25 men in their 60s took testosterone. AbbVie, a subsidiary of Abbott Laboratories, spent $80 million in 2012 on aggressive marketing campaigns featuring older men or retired athletes that strive to show how beneficial the product has been in their lives. Their product AndroGel 1.62% has generated over $1 billion in sales that year alone and has since become the top-selling product in the United States. In 2013, the gel grossed about $1.4 billion and commanded about 60% of the testosterone replacement therapy (TRT) market. The combination of effective marketing and ignorance of doctors have allowed for TRT to be readily available to anyone showing signs of low-T. Instead of taking a blood test to get the correct information for hypogonadism (low-T), the symptoms that provide reasoning for taking products such as AndroGel 1.62% include:

• Lack of energy
• Loss of libido
• Depression
• Loss of muscle mass

Why do Men use Testosterone Supplements? Men start to see about a 1% drop each year in testosterone because of aging. Furthermore, AndroGel 1.62% has not been approved for age-related declines in testosterone. In February of 2014, 5 men between the ages of 50-63 sued Abbott Laboratories due to heart attacks and strokes. One man in particular, 54 year old Michael Gallagher of Virginia suffered myocardial infarction, congestive heart failure & other injures after having no medical history of cardiac problems before taking Androgel 1.62%. Michael, along with the other men, blames the manufacturer for false statement of benefits linked with low-T drugs when compared to major risks. By March, there was a motion to consolidate more than three dozen pending federal lawsuits against the makers through a multidistrict litigation in its home territory, Illinois. Since then, the FDA remarked on the issues associated with the product at the beginning of 2015 by issuing a safety warning stating that testosterone drugs may increase the risk of stroke, heart attack and death. Although the FDA and pharmaceutical giants are trying to make up for lost time, that doesn't mean the damage that's already occurred can be swept under the rug when the market for TRT drugs are at an all time high. Contact the Litigation Team at Dolman Law Group Accident Injury Lawyers, PA for help with AndroGel If you or anyone you know is suffering from cardiac issues after using Androgel 1.62%, please call(833) 606-DRUG [3784] to speak with an attorney who thoroughly knows about defective drugs and deceptive marketing. Dolman Law Group Accident Injury Lawyers, PA 800 North Belcher Road Clearwater, FL 33765 (833) 606-DRUG [3784] https://www.dolmanlaw.com/legal-services/defective-medication-attorneys/